Articles tagged with Human Immunodeficiency Virus
Researchers have developed vaginal rings that can deliver therapeutic levels of two anti-HIV drugs for up to 30 days, while quick-dissolve films and almond-shaped tablets also show potential. These new formulations offer an alternative to daily microbicide gels and could provide a safer and more effective way to prevent HIV transmission.
Researchers found that children born to HIV-positive mothers with specific TLR9 gene variants are at a higher risk of acquiring the virus. The study confirms the relevance of innate immunity in perinatal HIV-1 infection and may lead to new therapeutic strategies.
Researchers tested a vaginal microbicide gel containing an integrase inhibitor and found it provided significant protection against infection with a virus similar to HIV. The study showed promise for further evaluation of integrase inhibitors as a potential method for preventing HIV transmission in uninfected individuals.
New scientific advances offer significant promise for reducing the spread of HIV/AIDS and tuberculosis, including novel TB drugs, rapid diagnostic tests and bold prevention approaches like PrEP. Experts call for policymakers to capitalize on these advances to save millions of lives from these deadly epidemics.
The global burden of tuberculosis remains significant, with 11 million active cases in 2008, despite progress made since the start of DOTS era. Rapid expansion of TB diagnosis and treatment has saved up to six million lives, but further efforts are needed to eliminate the disease by 2050.
Implementing the 3Is policy (Intensified tuberculosis case finding, Infection control, and Isoniazid preventive therapy) combined with earlier start of ART can prevent HIV-associated TB. Early diagnosis and treatment, along with a comprehensive package of HIV care, form the basis of prevention and control of HIV-associated TB.
Researchers found that vaccinia immunization reduces HIV replication, suggesting it could provide protection against subsequent infection. The decline of smallpox vaccination in the mid-20th century may have led to a loss of this protection, contributing to HIV's rapid contemporary spread.
A recent study found that frequent alcohol consumption is associated with a faster decline in CD4+ cell counts in individuals with HIV disease. The research, conducted over 30 months, suggests that alcohol has a direct impact on CD4 cells and accelerates immune system decline.
A prescription drug, imiquimod, has been found to boost the effectiveness of future vaccines for bacterial and viral diseases like HIV and hepatitis C. Scientists have coated imiquimod with dextran-based microparticles, significantly increasing the efficiency of cellular uptake by immune cells.
Researchers have discovered that individuals with a specific HLA B57 gene carry more potent killer T cells, which can recognize and attack HIV-infected cells. This finding may lead to the development of vaccines that provoke a similar response in people without the gene.
LA BioMed is participating in the international IPM020 study of a dapivirine-containing microbicide gel to evaluate its safety and absorption. The study aims to reduce HIV transmission among women, with the goal of reducing the cycle of infection that has led to millions of deaths worldwide.
The International Treatment Preparedness Group's new report documents early warning signs of devastating impact from global pullback on AIDS commitment and funding. People living with HIV often struggle to afford medicines for opportunistic infections, transport costs, food, and second-line medications.
New research identifies the source of 'noise' in HIV gene expression, finding that transcriptional bursting generates exceptionally high levels of noise. This finding suggests that latency may be fundamental to the HIV life cycle.
The latest data on maternal mortality show significant progress in reducing deaths in countries like China, Egypt, Ecuador, and Bolivia. However, unexpected increases were found in the US, Canada, and Denmark. The analysis revealed that the number of women dying from pregnancy-related causes has dropped by over 35% globally since 1980.
The global maternal mortality ratio declined from 422 in 1980 to 320 in 1990 and 251 in 2008, with developing countries making significant progress. The study found that HIV accounts for nearly one out of every five maternal deaths, with six countries accounting for more than half of all maternal deaths.
A new study found that community-based organizations can effectively implement an evidence-based HIV/STD risk-reduction intervention with adolescents. The intervention increased condom-protected intercourse without reducing the frequency of sexual activity.
Researchers at Duke University found that Peregrine's PS-targeting antibodies can block the CCR5 receptor, a key portal for HIV to gain entry into blood cells. The study showed potent ability to induce specific effects that impact viruses, inducing β-chemokines to block HIV entry.
Researchers at Duke University Medical Center have discovered a set of naturally occurring antibodies that can block HIV's entry into certain blood cells. These polyreactive anti-phospholipid antibodies show promise as a potential new strategy for HIV vaccine design.
Researchers have uncovered the three-dimensional structure of a key protein found on the surface of a specific HIV-1 subgroup, providing valuable insights for vaccine design. The discovery reveals unusual autoreactivity between an anti-HIV antibody and the CD4 receptor, raising questions about potential autoimmune responses.
A novel stem cell therapy has been developed to arm the immune system against HIV, potentially improving quality of life and life expectancy for those who have failed antiviral drugs. The therapy involves delivering antiviral DNA to patient immune cells, which can block viral gene production using RNA interference.
A study analyzed factors associated with HBsAg loss in HIV-HBV co-infected patients. Higher baseline CD4 cell counts were linked to increased loss of HBsAg, suggesting effective T-cell response against HBV. The research contributes to understanding predictors of HBsAg loss and its implications for management.
A UCSF study found that delivering HIV prevention services to people living with HIV in clinical settings can sharply reduce their sexual risk behaviors. The intervention, led by medical care providers during routine visits, resulted in a consistent decline in risky behavior over the 12-month study period.
Researchers have identified BanLec, a lectin in bananas, as an effective anti-HIV agent that can inhibit HIV infection by binding to the sugar-rich HIV-1 envelope protein. This discovery could lead to the development of new microcides to prevent sexual transmission of HIV.
Researchers identify a new reservoir for hidden HIV-infected cells in bone marrow, which can serve as a factory for new infections. The discovery opens up new possibilities for treating HIV, particularly for individuals who have been taking anti-viral drugs for their entire life.
Researchers at Universite de Montreal and VGTI have discovered a new mechanism by which HIV infects immune cells, characterizing the role of two molecules PD-1 and IL-10 in this process. The study suggests that blocking these interactions may restore the immune response in HIV-infected patients.
A new HIV vaccine strategy, called 'mosaic vaccines,' has shown promise in expanding immune responses in rhesus monkeys. The approach uses computational methods to create small sets of highly variable artificial viral proteins that stimulate a strong immune response against the diverse forms of HIV.
A systematic review found inadequate coverage of effective interventions for HIV prevention among injecting drug users globally. Only 8% of injectors have accessed needle and syringe programs in the last year, with coverage varying greatly between countries.
A new study published in the New England Journal of Medicine found that initiating antiretroviral therapy during tuberculosis treatment significantly reduces mortality rates for co-infected patients. The trial, which involved 642 patients, showed a 56% reduction in mortality rates compared to those who received sequential therapy.
A comprehensive population-based study by BC-CfE found that increased HAART coverage was associated with a significant decrease in new yearly HIV infections among injection drug users, resulting in improved health outcomes. The initiative aims to expand HIV treatment and care services for hard-to-reach populations.
Researchers from the University of Pennsylvania School of Medicine presented Phase II trial data on Lexgenleucel-T, a cell and gene therapy product for HIV treatment. The study showed 88% of evaluable subjects had a decrease in viral load set point, with one subject maintaining complete control of HIV viremia for over 14 weeks.
Researchers aim to improve contraceptive use and reduce unintended pregnancies among HIV-positive women in Kenya. The study, supported by the Bill and Melinda Gates Foundation, will evaluate an integrated model of HIV care and family planning services.
A new study confirms that single-dose nevirapine can lead to HIV treatment failure in women, but only if they start full antiretroviral therapy within a year after the dose. The risk of failure decreases significantly after 12 months.
Researchers at the University of California, San Diego, have discovered that HIV RNA in seminal plasma is transmitted during sex, not HIV DNA. This finding has significant implications for developing prevention strategies, including vaccines and microbicides to prevent the spread of sexually transmitted HIV.
A recent study found that the majority of TB-HIV co-infection cases in San Diego are now among Hispanics, highlighting a significant shift in the disease's ethnic makeup. The results emphasize the need for targeted binational prevention efforts to address the widening health disparities.
Researchers identified two compounds that bind to novel parts of the HIV protease enzyme, which could improve potency of existing treatments and combat drug-resistant strains. These findings open a new approach to drug design against HIV protease, targeting non-active sites that may help restore effectiveness against resistant superbugs.
A new study has found that acyclovir, a common medication used to treat herpes symptoms, does not reduce the transmission of HIV. The research, conducted in seven sub-Saharan countries, suggests that frequent genital herpes recurrences can increase HIV levels in the blood and genital tract.
Researchers have developed a new compound, EFdA, that is 60,000 times more potent than current HIV therapies and can protect cells for longer periods. This compound has the potential to be used in vaginal gels or creams as an alternative preventative strategy for women whose partners refuse to use condoms.
Researchers found HIV reduces brain blood flow even among young patients, accelerating the aging process. Blood flow in HIV brains is comparable to that of uninfected individuals 15-20 years older.
Researchers found that PrEP prevented rectal and intravenous HIV transmission in humanized mice with 90% protection rate. The study suggests PrEP can block multiple routes of HIV transmission, providing a promising approach to prevent new infections.
A five-year international study found that acyclovir suppressive therapy did not reduce the risk of HIV transmission in couples where one partner had both HIV and HSV-2. The study revealed significant reductions in plasma HIV levels and genital ulcers, but no impact on HIV transmission.
A Cochrane Systematic Review found that home-based nursing in HIV/AIDS patients significantly improves self-reported knowledge of HIV, awareness of medications, and self-reported adherence to medication programmes. Home-based care also had a positive impact on HIV stigma, worry, and physical functioning.
A recent study found that HIV patients who switch from lopinavir-ritonavir to raltegravir experience a reduction in blood fat levels, but the rate of viral suppression is lower in the raltegravir group. The results suggest that clinicians need to consider individual patient factors when making treatment decisions.
Researchers found that unique reading frames in the HIV genome can induce immune responses, potentially leading to new ways to combat the virus. These findings may prove useful for developing more effective HIV vaccines.
A study published by The Translational Genomics Research Institute found that circumcision significantly alters the bacterial communities of the penis, reducing anaerobic bacteria and increasing aerobic bacteria. This change may contribute to lower HIV risk and protection against bacterial vaginosis in women.
Researchers at the Gladstone Institutes have discovered surfen, a small molecule that inhibits HIV's ability to bind to cells and enhance infection. The discovery could lead to new treatments for HIV, potentially reducing transmission rates through sexual contact.
UCSF researchers found that offering rapid HIV tests to patients in community health centers significantly increases the number of patients screened for HIV. The study saw a nearly three-fold increase in screenings from 3,000 to over 11,000 patients.
New research suggests HIV-related cognitive deficits share a common link with Alzheimer's-related dementia: low levels of the protein amyloid beta in spinal fluid. This study can help find the cause of cognitive impairment in HIV patients and may impact new Alzheimer's treatments.
The November issue of Reproductive Health Matters explores the complex relationship between criminalization and HIV transmission, raising concerns about women's rights in Africa. The journal examines how laws aimed at protecting women from sexual violence may inadvertently lead to their prosecution for HIV exposure.
A meta-analysis of 10 studies involving 1862 HIV patients found no statistically significant difference between directly observed and self-administered antiretroviral therapy in promoting virological suppression. This suggests that directly observed therapy may not be necessary to support adherence in the general patient population.
A new study finds that approximately 31% of patients with HIV report an improved quality of life after diagnosis. The main factors associated with this improvement are optimism and spirituality, while lower levels of these traits can lead to a perceived decline in quality of life.
Researchers found that unacculturated Hispanics had fewer HIV tests and were more likely to test positive. Interventions must address cultural differences to reduce the growing rate of HIV/AIDS among Hispanics.
A recent study published in The Lancet found that home-based HIV care is an effective strategy, relying less on clinical staff and hospital services than facility-based care. This approach provides large savings for patients and could improve equitable access to HIV treatment, especially in areas with scarce clinical infrastructure.
A recent study found that only 60% of pregnant women in Eastern and Southern Africa were tested for HIV in 2007. The authors suggest that women may be avoiding testing due to opt-out policies or concerns about the stigma associated with HIV. This highlights the need for increased awareness and access to HIV screening in these regions.
Scientists discover that antibodies must precisely target the gp120 site of initial attachment on the viral spike to neutralize HIV. The new findings suggest a potential strategy for generating effective HIV-neutralizing antibodies, which could bring researchers closer to creating an HIV vaccine.
Researchers found that people who had previously built up immunity to the adenovirus used in the trial had a higher risk of infection with HIV after receiving the vaccine. The study suggests that other adenovirus-based vaccines, such as those for tuberculosis and malaria, may also be at risk due to the same immune system reaction.
Researchers at the University of Pittsburgh School of Medicine have identified a functional importance seam in the HIV coat that could lead to new treatments for blocking HIV infection. The findings may allow scientists to rationally design therapeutic compounds that interfere with assembly and function of the protein.
Researchers at German Cancer Research Center find that HIV virus rarely integrates into genes with high transcription activity. This discovery could lead to the development of specific AIDS drugs targeting these 'cold spots', potentially offering a new approach to combat the virus.
Scientists have identified a key mechanism behind the binding action of HIV antibodies 2F5 and 4E10, which could lead to the development of more effective vaccines. The study found that successful docking requires attachment to the virus's membrane containing lipid.
A study by Indiana University found that using lubricants during sex significantly improves the pleasurable and satisfying aspects of sexual activity for both men and women. The research also showed that vaginal tearing is rare when lubricant is used, occurring in less than 1% of cases.
Researchers at Yale University developed synthetic molecules that enhance the body's immune response to HIV and prostate cancer cells. The molecules work by binding to antibodies and proteins on infected cells, triggering an immune response and preventing infection.